Trial · NCT02624869
Adverse events87
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 87
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain upper | Gastrointestinal disorders | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 1 | 49 | |
| other | Abdominal pain upper | Gastrointestinal disorders | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 5 | 101 | |
| other | Abdominal pain upper | Gastrointestinal disorders | HoFH: Evolocumab 420 mg QM | 1 | 12 | |
| other | Nausea | Gastrointestinal disorders | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 0 | 49 | |
| other | Nausea | Gastrointestinal disorders | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 1 | 101 | |
| other | Nausea | Gastrointestinal disorders | HoFH: Evolocumab 420 mg QM | 1 | 12 | |
| other | Fatigue | General disorders | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 4 | 49 | |
| other | Fatigue | General disorders | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 3 | 101 | |
| other | Fatigue | General disorders | HoFH: Evolocumab 420 mg QM | 0 | 12 | |
| other | Influenza like illness | General disorders | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 5 | 49 | |
| other | Influenza like illness | General disorders | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 8 | 101 | |
| other | Influenza like illness | General disorders | HoFH: Evolocumab 420 mg QM | 0 | 12 | |
| other | Injection site erythema | General disorders | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 4 | 49 | |
| other | Injection site erythema | General disorders | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 1 | 101 | |
| other | Injection site erythema | General disorders | HoFH: Evolocumab 420 mg QM | 0 | 12 | |
| other | Injection site haemorrhage | General disorders | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 0 | 49 | |
| other | Injection site haemorrhage | General disorders | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 1 | 101 | |
| other | Injection site haemorrhage | General disorders | HoFH: Evolocumab 420 mg QM | 1 | 12 | |
| other | Pyrexia | General disorders | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 5 | 49 | |
| other | Pyrexia | General disorders | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 1 | 101 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02624869/events